Production (Stage)
Pasithea Therapeutics Corp.
KTTA
$0.69
$0.00070.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.44% | 12.89% | 1.60% | 3.63% | -2.42% |
| Total Depreciation and Amortization | -0.09% | 0.09% | 32.38% | 97.87% | 289.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 75.30% | 171.47% | 134.06% | 320.70% | -34.45% |
| Change in Net Operating Assets | -127.31% | -196.52% | -128.87% | -88.34% | 30.59% |
| Cash from Operations | 11.86% | -3.71% | -6.10% | 7.14% | 1.05% |
| Capital Expenditure | -- | -- | 100.00% | 114.63% | 112.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -0.91% | 198.18% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -28.23% | -100.00% | 151.65% |
| Cash from Investing | -- | -- | 143.46% | 104.84% | 115.21% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | 100.00% | 48.55% | -105.85% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | 100.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 103,385.71% | -- | -- | -- | -103.79% |
| Cash from Financing | 249.99% | 221.23% | 165.50% | -25.61% | -41.09% |
| Foreign Exchange rate Adjustments | 9.52% | 37.50% | -120.79% | -108.69% | -117.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 62.76% | 43.85% | 55.15% | 12.09% | 11.85% |